Revenue $1.46B, up 8.6% on a year earlier. Americas Revenue $853.00M, up 7.7%. Europe and Asia Pacific revenue $439.00M, up 12.9%. Diluted EPS $2.64 against $2.58.
| Q4 FY26 | Q3 FY26 | Q4 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $1.46B | $1.43B | $1.35B | +8.6% |
| Operating income | $448.71M | $499.81M | $454.54M | -1.3% |
| Net income | $383.43M | $398.73M | $379.70M | +1.0% |
| Diluted EPS | $2.64 | $2.74 | $2.58 | |
| Operating cash flow | $454.63M | $554.13M | $538.77M | -15.6% |
| Capital expenditures | -$51.13M | -$33.65M | -$30.59M | |
| Free cash flow | $403.50M | $520.48M | $508.18M | -20.6% |
| Dividend per share | $0.60 | $0.60 | $0.53 |
| Q4 FY26 | Q4 FY25 | Year over year | |
|---|---|---|---|
| Americas Revenue | $853.00M | $791.90M | +7.7% |
| Europe and Asia Pacific revenue | $439.00M | $389.00M | +12.9% |
| Net revenue growth | 9% | 10.2% | |
| Revenue Growth (Constant Currency) | 8% | 9% | |
| Americas revenue growth | 8% | 9% | |
| Europe and Asia Pacific revenue growth constant currency | 10% | 9% | |
| Europe and Asia Pacific revenue growth | 13% | 13% | |
| Masks and other Revenue | $394.00M | $487.10M | -19.1% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Resmed (RMD) Q4 FY26 earnings: results and KPIs”, stockatlas.com/companies/RMD/earnings/2026-q4/, data as of 3 November 2026. Links to this page are welcome.
